PharmD Info

A forum for Indian Pharmacy Professionals

Important: Registered today to have the complete access on this forum --- Register Here
It's an open forum for Indian Clinical and Hospital Pharmacists to discuss on designing, implementing, and monitoring a therapeutic plan that will produce specific therapeutic outcomes for the patient Eg:Antibiotic Policies, Pharmacist Interventions, Medication Therapy Management. DRP,s and Its Management.
Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
  • User avatar
#2017
There are few available options for treating Pulmonary hypertension in COPD and this statement may help a better understanding.

"Long-term supplemental oxygen remains the primary treatment in COPD patients with PH. The administration of new vasodilators (prostanoids, endothelin-1 receptor antagonists and phosphodiesterase-5 inhibitors) dedicated to idiopathic pulmonary arterial hypertension in the disproportionate subgroup of patients with "out-of-proportion" PH may be considered in the setting of clinical trials. The use of these drugs in COPD patients with PH < 40 mmHg may worsen gas exchange, and to date, has no proven benefit.

Further novel agents under review/trials are "5-HT receptor antagonists, Rho-kinase inhibitors, statins and stem cell therapy.

Reference:Curr Drug Targets. 2011 Apr;12(4):501-13.
Pulmonary hypertension in COPD: pathophysiology and therapeutic targets.
Zakynthinos E1, Daniil Z, Papanikolaou J, Makris D.
Similar Topics
Topics Statistics Last post
0 Replies 
372 Views
by rahmatulla.syed
17 Jan 2018, 18:59
0 Replies 
817 Views
by Admin
08 Apr 2018, 22:44
0 Replies 
888 Views
by Admin
21 May 2017, 22:34
0 Replies 
1194 Views
by Admin
16 Sep 2017, 18:17
12 Replies 
1846 Views
by Diya Varghese Wilson
06 Oct 2017, 11:01

Tags

PharmD Info Online Group Discussion Disc[…]

The Pharmacy Council of India (PCI) has launched a[…]

Indian Association of Colleges of Pharmacy. A/C N[…]

PCI chalks out plans to allay concerns of educatio[…]

WELCOME TO OUR E-LEARN COURSE WORK MODULES